Asset Details
Do you wish to reserve the book?
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Do you wish to request the book?
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vericiguat in advanced heart failure patients receiving chronic intermittent levosimendan infusions: a prospective pilot study
2026
Overview
BackgroundAlthough treatment options for heart failure (HF) have improved, advanced HF (AdHF) remains a challenging condition, impacting over 10% of patients with a poor prognosis. In severe cases, patients may experience resistance to or intolerance of conventional therapies, leading to frequent hospitalisations and a heightened risk of death. Vericiguat, a novel treatment for HF with reduced ejection fraction (HFrEF), has shown promise in improving outcomes for patients with worsening HF. The VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial demonstrated that vericiguat can reduce the risk of adverse events in patients with EF<45% following a worsening HF event. However, its safety and efficacy in AdHF patients previously receiving chronic levosimendan infusions remain unclear.Methods and resultsIn this prospective study, we evaluated the safety and tolerability of vericiguat in AdHF patients treated with monthly levosimendan infusions at our clinic. Among 18 patients, 8 were eligible for vericiguat, which was associated with better echocardiographic findings, improved quality of life and lower 1-year mortality compared with non-eligible patients. However, 37.5% of patients discontinued the drug due to symptomatic hypotension, highlighting a key challenge in managing this fragile population. Despite this, vericiguat was generally well-tolerated, and no severe adverse effects were observed.DiscussionThis study provides the first prospective evidence supporting the safe use of vericiguat in AdHF patients on chronic levosimendan. However, careful monitoring for hypotension is essential, and titration may be more difficult in this population. Further research is needed to optimise treatment strategies for these high-risk patients.
Publisher
BMJ Publishing Group Ltd and British Cardiovascular Society,BMJ Publishing Group LTD
Subject
/ Cardiotonic Agents - administration & dosage
/ Cardiotonic Agents - adverse effects
/ Drug Administration Schedule
/ Enzymes
/ Female
/ Heart Failure - drug therapy
/ Heart Failure - physiopathology
/ Heterocyclic Compounds, 2-Ring
/ Humans
/ Hydrazones - administration & dosage
/ Hydrazones - adverse effects
/ Male
/ Peptides
/ Pyridazines - administration & dosage
/ Pyridazines - adverse effects
/ Simendan - administration & dosage
